WCWanlin Cui

Wanlin Cui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wanlin Cui has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease

    by Haitao Chu, Xin Song, Chang Liu, Tianjiao Ma, Wanlin Cui

    The gut microbiota exerts broad control over host physiology through tightly coordinated metabolic networks. Among these, bile salt hydrolase (BSH), a microbial enzyme, serves as a key mediator of microbiota–host crosstalk. As a key upstream gateway reaction in bile acid metabolism, BSH hydrolyzes conjugated bile acids and reshapes the composition and distribution of the intestinal bile acid pool. This remodeling alters bile acid signaling quality and influences the host energy metabolism, immune homeostasis and intestinal barrier integrity. In this review, we summarize the core biological functions and molecular regulatory mechanisms of microbial BSH in maintaining digestive system homeostasis. We further discuss the association between BSH dysregulation and the development of major digestive diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD), inflammatory bowel disease (IBD) and colorectal cancer (CRC). Finally, we outline emerging precision strategies targeting BSH, including strain-specific probiotics, enzyme activity modulators and dietary interventions. These approaches offer a conceptual framework for microbiota-based therapies in digestive diseases.


  • Open Access

    Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention

    by Shen Pan, Hehe Zhu, Rui Yin, Jiaman Lin, Zhujun Wang, Wanlin Cui, Zhenhua Li, Bitian Liu

    Bladder cancer remains a significant global health concern, with environmental carcinogen exposure—particularly from tobacco-derived compounds such as aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and nitrosamines—recognized as a primary etiological factor. These carcinogens undergo complex metabolic activation in the liver, bladder epithelium, and gut microbiota, generating reactive intermediates that initiate DNA damage, oxidative stress, and pro-tumorigenic signaling. This review synthesizes emerging evidence on how carcinogen-induced metabolic reprogramming contributes to bladder cancer initiation and progression, emphasizing the roles of key genetic pathways and metabolic enzymes involved in xenobiotic detoxification, DNA repair, and redox regulation. In parallel, we examine the influence of gut microbiota on carcinogen bioactivation and biotransformation, highlighting its dual role as both a metabolic modulator and a potential preventive target. We critically evaluate human observational data linking microbiome dysbiosis to bladder cancer risk, while addressing limitations such as small cohort sizes and confounders like diet and age. Finally, we discuss promising strategies for risk mitigation, including microbiome-directed interventions, dietary modulation, and chemopreventive agents that counteract carcinogenic effects. By integrating molecular oncology, toxicogenomics, and host-microbiome interactions, this review provides a mechanistic framework for understanding bladder cancer etiology and identifies novel opportunities for preventive and precision interventions.